Boxer Capital and Medivation News

This is selected news for Boxer Capital and Medivation, which are filed under Capital Firms and Sectors / Healthtech, respectively.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
10/29/2019 Nuvation Bio Pulls In $275M
... Bio led, structured and syndicated by Omega Funds and included participation from leading biotechnology investors including Aisling Capital, Altitude Life Science Ventures, The Baupost Group, Boxer Capital of the Tavistock Group, EDBI (global Asian-based Investor), ECOR1 Capital, Fidelity Management and Research Company, Pavilion Capital, Perceptive Advisors, Redmile Group, Surveyor ...
vcnewsdaily.com
10/28/2019 David Hung and ex-Medivation execs join forces for stealthy cancer startup
David Hung, M.D., has had a strange few years: From the man who led Medivation to being snapped up by Pfizer in a major $14 billion M&A deal, he then went over to Axovant, where it went very wrong. He's now looking to turn things around. Last year, he ...
FierceBiotech
10/28/2019 Hung, ex-Medivation execs join forces for stealthy cancer startup
... by Omega Funds, it said in a statement, with a host of others chipping in, including: Aisling Capital, Altitude Life Science Ventures, The Baupost Group, Boxer Capital of the Tavistock Group, EDBI (a global Asia-based investor), ECOR1 Capital, Fidelity Management and Research Company, Pavilion Capital, Perceptive Advisors, Redmile Group ...
FierceBiotech
10/28/2019 Oncology Start-Up Nuvation Bio Closes $275 Million Series A Financing Led by Omega Funds
... its oncology programs. Nuvation Bio was founded by industry veteran David Hung , M.D., who previously founded and served as President and Chief Executive Officer of Medivation, Inc., which was subsequently sold to Pfizer, Inc. for $14.3 billion in 2016. "My vision for Nuvation Bio is to provide patients with dramatic ...
PR Newswire
10/28/2019 Oncology Start-Up Nuvation Bio Closes $275 Million Series A Financing Led by Omega Funds
... was led, structured and syndicated by Omega Funds and included participation from leading biotechnology investors including Aisling Capital, Altitude Life Science Ventures, The Baupost Group, Boxer Capital of the Tavistock Group, EDBI (global Asian-based Investor), ECOR1 Capital, Fidelity Management and Research Company, Pavilion Capital, Perceptive Advisors, Redmile Group, Surveyor ...
BioSpace